Abbott Laboratories $ABT Shares Sold by One Wealth Advisors LLC

One Wealth Advisors LLC lessened its position in Abbott Laboratories (NYSE:ABT) by 40.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,638 shares of the healthcare product maker’s stock after selling 1,760 shares during the period. One Wealth Advisors LLC’s holdings in Abbott Laboratories were worth $359,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of ABT. Brighton Jones LLC grew its holdings in Abbott Laboratories by 10.1% in the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after purchasing an additional 4,755 shares during the period. Fragasso Financial Advisors Inc grew its holdings in Abbott Laboratories by 3.2% in the first quarter. Fragasso Financial Advisors Inc now owns 6,150 shares of the healthcare product maker’s stock valued at $816,000 after purchasing an additional 188 shares during the period. Merit Financial Group LLC grew its holdings in Abbott Laboratories by 7.9% in the first quarter. Merit Financial Group LLC now owns 54,329 shares of the healthcare product maker’s stock valued at $7,207,000 after purchasing an additional 3,989 shares during the period. ST Germain D J Co. Inc. grew its holdings in Abbott Laboratories by 2.3% in the first quarter. ST Germain D J Co. Inc. now owns 21,101 shares of the healthcare product maker’s stock valued at $2,799,000 after purchasing an additional 469 shares during the period. Finally, HBW Advisory Services LLC grew its holdings in Abbott Laboratories by 53.9% in the first quarter. HBW Advisory Services LLC now owns 3,263 shares of the healthcare product maker’s stock valued at $433,000 after purchasing an additional 1,143 shares during the period. Institutional investors and hedge funds own 75.18% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Wells Fargo & Company lowered their target price on shares of Abbott Laboratories from $147.00 to $142.00 and set an “overweight” rating for the company in a report on Friday, July 18th. Leerink Partners began coverage on shares of Abbott Laboratories in a research note on Monday, June 16th. They set a “market perform” rating and a $143.00 price objective for the company. Evercore ISI boosted their price objective on shares of Abbott Laboratories from $140.00 to $145.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 8th. Mizuho boosted their price objective on shares of Abbott Laboratories from $130.00 to $140.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 16th. Finally, Leerink Partnrs upgraded shares of Abbott Laboratories to a “hold” rating in a research note on Monday, June 16th. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $145.22.

Abbott Laboratories Price Performance

Shares of ABT stock opened at $133.97 on Wednesday. The company has a market capitalization of $233.17 billion, a PE ratio of 16.79, a price-to-earnings-growth ratio of 2.52 and a beta of 0.69. The firm has a fifty day simple moving average of $131.48 and a 200-day simple moving average of $131.22. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25. Abbott Laboratories has a twelve month low of $110.86 and a twelve month high of $141.23.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, meeting the consensus estimate of $1.26. The business had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The business’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Equities research analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be issued a $0.59 dividend. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $2.36 annualized dividend and a yield of 1.8%. Abbott Laboratories’s dividend payout ratio is currently 29.57%.

Insider Transactions at Abbott Laboratories

In related news, CFO Philip P. Boudreau sold 5,550 shares of the company’s stock in a transaction on Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the sale, the chief financial officer directly owned 51,003 shares of the company’s stock, valued at $6,862,453.65. This represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.46% of the stock is owned by corporate insiders.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.